Catheter-related Bloodstream Infections Market

Catheter-related Bloodstream Infections Market (Treatment Type: Anti-microbial Agents and Antibiotic Lock Therapy) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Catheter-related Bloodstream Infections Market Outlook 2031

  • The industry was valued at US$ 1.3 Bn in 2021
  • It is projected to grow at a CAGR of 5.1% from 2022 to 2031 and reach more than US$ 2.0 Bn by the end of 2031

Analysts’ Viewpoint

Growth in aging population, rise in prevalence of chronic diseases, and increase in number of invasive medical procedures are driving the global catheter-related bloodstream infections market. Surge in number of surgeries and increase in number of patients requiring catheterization are also expected to fuel market expansion.

Increase in adoption of advanced technologies & products for CRBSI infection prevention and treatment, such as antimicrobial-coated catheters and improved diagnostic methods, is presenting significant opportunities for market players.

Leading players are focusing on the development of advanced, safe, and cost-effective products. Government initiatives to promote patient safety and increase in awareness about CRBSIs among healthcare professionals and patients are likely to augment market progress.

Catheter Related Bloodstream Infections Market

Catheter-related Bloodstream Infections Market Introduction

Catheter-related bloodstream infection (CRBSI) can be defined as presence of bacteremia after the usage of intravenous catheter. It is a frequent and severe complication of central venous catheterization, and a common cause of nosocomial bacteremia.

Integral to modern practice, intravascular catheters are used for critically-ill patients for administration of fluids, blood products, medication, nutritional solutions, and for hemodynamic monitoring.

Central venous catheters (CVCs) present a significant risk of device-related infections than any other type of medical devices. CVCs are also major causes of morbidity and mortality. These are also the primary source of bacteremia and septicemia in hospitalized patients.

Rise in Prevalence of Bloodstream Infections

Rise in number of invasive medical procedures performed, such as surgeries and cancer treatments that require the use of catheters, increases the risk of infection. This results in higher demand for products and services related to prevention and treatment of these infections. Usage of catheter for a long duration increases the chances of infection. Thus, rise in number of invasive medical procedures is a key driver of the catheter-related bloodstream infection market.

Surge in prevalence of antibiotic-resistant bacteria is another prominent market catalyst. Rise in antibiotic-resistant infections is leading to an increase in demand for products and services that could help prevent and treat these infections.

Rise in prevalence of bloodstream infections, increase in awareness, surge in adoption of minimally invasive procedures, growth in prevalence of antibiotic-resistant bacteria, and higher demand for more effective and safer products are fueling the catheter-related bloodstream infections market.

Increase in Global Geriatric Population

Growth in aging population is one of the key drivers of the catheter associated bloodstream infections market. The global population over 60 years is expected to double from 11% to 22% between 2000 and 2050. The number of people aged 60 and above is anticipated to increase from 605 million to 2.1 billion during the period.

Incidence of chronic diseases such as diabetes and heart diseases rises with age. This, in turn, increases the risk of CRBSI infections, resulting in higher demand for products and services related to prevention and treatment of these infections.

Aging population is driving the global catheter-related bloodstream infections industry, as older individuals are more likely to require invasive medical procedures. Elderly people are more likely to develop chronic conditions, such as cancer, heart diseases, and diabetes, which require treatment. Several of these conditions require the use of catheters, which increases the risk of CRBSI infection. Hence, older individuals are more likely to develop CRBSI infection and require treatment. Thus, surge in geriatric population is expected to increase the catheter-related bloodstream infections market size.

Growth in Demand for Antimicrobial Agents

In terms of treatment type, the anti-microbial agents segment accounted for the largest market share of more than 75% in 2021. This trend is expected to continue during the forecast period.

Anti-microbial agents, such as antibiotics, can help treat catheter-related bloodstream infections by killing or inhibiting the growth of bacteria that have colonized the catheter or have entered the bloodstream through the catheter. These agents can be administered orally, intravenously, or topically.

It is important to use the appropriate antibiotic based on the type of bacteria causing the infection. It is equally vital to continue treatment for the recommended duration to ensure the infection is fully cleared.

Patient Preference for Hospital Pharmacies

Based on distribution channel, the hospital pharmacies segment dominated the global catheter-related bloodstream infections market in 2021. Most patients prefer hospital pharmacies owing to the convenience of treatment and availability of medicines offered at hospitals. Furthermore, proper diagnosis and availability of multiple options for treating catheter-related bloodstream infections are leading to an increase in number of patient visits to hospital pharmacies. Thus, the hospital pharmacies segment held around 55.0% share of the global market in 2021.

Regional Analysis

According to catheter-related bloodstream infections industry analysis, North America held the largest share of the global market in 2021. This trend is expected to continue during the forecast period primarily due to the presence of well-established health care infrastructure and technological advancements in the healthcare sector to treat blood-related infections.

Increase in number of people suffering from catheter-related blood infections in the U.S. and Canada, especially the geriatric population, is driving the market in North America. Furthermore, availability of various treatments for catheter associated bloodstream infections is propelling the market in the region.

The market in Asia Pacific is projected to grow at a rapid pace during the forecast period owing to the rise in prevalence of hospital-acquired infections. According to the World Health Organization's Department of Communicable Disease, the risk of healthcare-associated infection is two to 20 times higher in developing countries than that in developed countries.

Analysis of Key Players in Global Catheter-Related Bloodstream Infections Market

The global market is highly consolidated, with the presence of small number of key players. These players hold major share in their respective regions. Demand for catheter-related bloodstream infection products has increased in emerging as well as developed markets due to the rise in prevalence of blood stream infections. Growth strategies and focus on research & development by key players are the factors likely to drive the global market.

Leading companies in the global catheter-related bloodstream infections market are Xellia Pharmaceuticals Ltd., Pfizer, Glenmark Pharmaceuticals Ltd., Fresenius Medical Care, CorMedix, Inc., TauroPhar GmbH, Geistlich Pharma, Citus Pharmaceuticals, AstraZeneca, and Merck & Co., Inc.

Key Developments in Global Catheter-related Bloodstream Infections Market

  • In December 2022, CorMedix presented highlights of a research conducted by integrating multiple clinical and claims databases that track a large group of kidney failure patients on hemodialysis (HD) with central venous catheters (CVCs). The company's primary focus is on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases caused by catheter-related bloodstream infections.

Prominent players have been profiled in the global catheter-related bloodstream infections market report based on parameters such as product portfolio, recent developments, financial overview, company overview, strategies, and segments.

Global Catheter-related Bloodstream Infections Market Snapshot

Attribute

Detail

Size in 2021

US$ 1.3 Bn

Forecast (Value) in 2031

More than US$ 2.0 Bn

Compound Annual Growth Rate (CAGR)

5.1%

Forecast Period

2022–2031

Historical Data Available for

2017–2021

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.

Competition Landscape

  • Market share analysis by company (2021)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Segmentation

  • Treatment Type
    • Anti-microbial Agents
    • Antibiotic Lock Therapy
  • Source of Infection
    • Coagulase-negative Staphylococcus
    • S. aureus
    • Enteric Gram-negative Bacilli
    • Yeasts
    • Enterococci & Streptococci
    • Pseudomonas
    • Others
  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Regions Covered

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • Japan
  • India
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • AstraZeneca
  • CorMedix, Inc.
  • Citus Pharmaceuticals
  • Fresenius Medical Care
  • Glenmark Pharmaceuticals Ltd.
  • Geistlich Pharma
  • Merck & Co., Inc.
  • Pfizer
  • TauroPhar GmbH
  • Xellia Pharmaceuticals Ltd.

Customization Scope

Available upon request

Pricing

Available upon request

Frequently Asked Questions

How big was the global catheter-related bloodstream infections market in 2021?

The global industry was valued at US$ 1.3 Bn in 2021

How big will it be by 2031?

It is projected to reach more than US$ 2.0 Bn by 2031

What will be the CAGR during the forecast period?

The CAGR is expected to be 5.1% from 2022 to 2031

Which are the prominent trends that affect growth?

Rise in prevalence of bloodstream infections and increase in global geriatric population

Who are the prominent players in the business?

Xellia Pharmaceuticals Ltd., Pfizer, Glenmark Pharmaceuticals Ltd., Fresenius Medical Care, CorMedix Inc., TauroPhar GmbH, Geistlich Pharma, Citus Pharmaceuticals, AstraZeneca, and Merck & Co., Inc.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Catheter-related Bloodstream Infections Market

    4. Market Overview

        4.1. Introduction

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Catheter-related Bloodstream Infections Market Analysis and Forecast, 2017–2031

            4.4.1. Market Revenue Projections (US$ Mn)

            4.4.2. Market Volume/Unit Shipments Projections

        4.5. Porter’s Five Forces Analysis

    5. Key Insights

        5.1. Disease Prevalence & Incidence Rate Globally With Key Countries

        5.2. Key Industry Events

        5.3. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)

    6. Global Catheter-related Bloodstream Infections Market Analysis and Forecast, by Treatment Type

        6.1. Introduction & Definition

        6.2. Key Findings/Developments

        6.3. Market Value Forecast, by Treatment Type, 2017–2031

            6.3.1. Anti-microbial Agents

            6.3.2. Antibiotic Lock Therapy

        6.4. Market Attractiveness Analysis, by Treatment Type

    7. Global Catheter-related Bloodstream Infections Market Analysis and Forecast, by Source of Infection

        7.1. Introduction & Definition

        7.2. Key Findings/Developments

        7.3. Market Value Forecast, by Source of Infection, 2017–2031

            7.3.1. Coagulase-negative Staphylococcus

            7.3.2. S. aureus

            7.3.3. Enteric Gram-negative Bacilli

            7.3.4. Yeasts

            7.3.5. Enterococci & Streptococci

            7.3.6. Pseudomonas

            7.3.7. Others

        7.4. Market Attractiveness Analysis, by Source of Infection

    8. Global Catheter-related Bloodstream Infections Market Analysis and Forecast, by Distribution Channel

        8.1. Introduction & Definition

        8.2. Key Findings/Developments

        8.3. Market Value Forecast, by Distribution Channel, 2017–2031

            8.3.1. Hospital Pharmacies

            8.3.2. Retail Pharmacies

            8.3.3. Online Pharmacies

        8.4. Market Attractiveness Analysis, by Distribution Channel

    9. Global Catheter-related Bloodstream Infections Market Analysis and Forecast, by Region

        9.1. Key Findings

        9.2. Market Value Forecast, by Region, 2017–2031

            9.2.1. North America

            9.2.2. Europe

            9.2.3. Asia Pacific

            9.2.4. Latin America

            9.2.5. Middle East & Africa

        9.3. Market Attractiveness Analysis, by Region

    10. North America Catheter-related Bloodstream Infections Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast, by Treatment Type, 2017–2031

            10.2.1. Anti-microbial Agents

            10.2.2. Antibiotic Lock Therapy

        10.3. Market Value Forecast, by Source of Infection, 2017–2031

            10.3.1. Coagulase-negative Staphylococcus

            10.3.2. S. aureus

            10.3.3. Enteric Gram-negative Bacilli

            10.3.4. Yeasts

            10.3.5. Enterococci & Streptococci

            10.3.6. Pseudomonas

            10.3.7. Others

        10.4. Market Value Forecast, by Distribution Channel, 2017–2031

            10.4.1. Hospital Pharmacies

            10.4.2. Retail Pharmacies

            10.4.3. Online Pharmacies

        10.5. Market Value Forecast, by Country, 2017–2031

            10.5.1. U.S.

            10.5.2. Canada

        10.6. Market Attractiveness Analysis

            10.6.1. By Treatment Type

            10.6.2. By Source of Infection

            10.6.3. By Distribution Channel

            10.6.4. By Country

    11. Europe Catheter-related Bloodstream Infections Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Treatment Type, 2017–2031

            11.2.1. Anti-microbial Agents

            11.2.2. Antibiotic Lock Therapy

        11.3. Market Value Forecast, by Source of Infection, 2017–2031

            11.3.1. Coagulase-negative Staphylococcus

            11.3.2. S. aureus

            11.3.3. Enteric Gram-negative Bacilli

            11.3.4. Yeasts

            11.3.5. Enterococci & Streptococci

            11.3.6. Pseudomonas

            11.3.7. Others

        11.4. Market Value Forecast, by Distribution Channel, 2017–2031

            11.4.1. Hospital Pharmacies

            11.4.2. Retail Pharmacies

            11.4.3. Online Pharmacies

        11.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            11.5.1. Germany

            11.5.2. U.K.

            11.5.3. France

            11.5.4. Italy

            11.5.5. Spain

            11.5.6. Rest of Europe

        11.6. Market Attractiveness Analysis

            11.6.1. By Treatment Type

            11.6.2. By Source of Infection

            11.6.3. By Distribution Channel

            11.6.4. By Country/Sub-region

    12. Asia Pacific Catheter-related Bloodstream Infections Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Treatment Type, 2017–2031

            12.2.1. Anti-microbial Agents

            12.2.2. Antibiotic Lock Therapy

        12.3. Market Value Forecast, by Source of Infection, 2017–2031

            12.3.1. Coagulase-negative Staphylococcus

            12.3.2. S. aureus

            12.3.3. Enteric Gram-negative Bacilli

            12.3.4. Yeasts

            12.3.5. Enterococci & Streptococci

            12.3.6. Pseudomonas

            12.3.7. Others

        12.4. Market Value Forecast, by Distribution Channel, 2017–2031

            12.4.1. Hospital Pharmacies

            12.4.2. Retail Pharmacies

            12.4.3. Online Pharmacies

        12.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            12.5.1. China

            12.5.2. Japan

            12.5.3. India

            12.5.4. Australia & New Zealand

            12.5.5. Rest of Asia Pacific

        12.6. Market Attractiveness Analysis

            12.6.1. By Treatment Type

            12.6.2. By Source of Infection

            12.6.3. By Distribution Channel

            12.6.4. By Country/Sub-region

    13. Latin America Catheter-related Bloodstream Infections Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Treatment Type, 2017–2031

            13.2.1. Anti-microbial Agents

            13.2.2. Antibiotic Lock Therapy

        13.3. Market Value Forecast, by Source of Infection, 2017–2031

            13.3.1. Coagulase-negative Staphylococcus

            13.3.2. S. aureus

            13.3.3. Enteric Gram-negative Bacilli

            13.3.4. Yeasts

            13.3.5. Enterococci & Streptococci

            13.3.6. Pseudomonas

            13.3.7. Others

        13.4. Market Value Forecast, by Distribution Channel, 2017–2031

            13.4.1. Hospital Pharmacies

            13.4.2. Retail Pharmacies

            13.4.3. Online Pharmacies

        13.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            13.5.1. Brazil

            13.5.2. Mexico

            13.5.3. Rest of Latin America

        13.6. Market Attractiveness Analysis

            13.6.1. By Treatment Type

            13.6.2. By Source of Infection

            13.6.3. By Distribution Channel

            13.6.4. By Country/Sub-region

    14. Middle East & Africa Catheter-related Bloodstream Infections Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast, by Treatment Type, 2017–2031

            14.2.1. Anti-microbial Agents

            14.2.2. Antibiotic Lock Therapy

        14.3. Market Value Forecast, by Source of Infection, 2017–2031

            14.3.1. Coagulase-negative Staphylococcus

            14.3.2. S. aureus

            14.3.3. Enteric Gram-negative Bacilli

            14.3.4. Yeasts

            14.3.5. Enterococci & Streptococci

            14.3.6. Pseudomonas

            14.3.7. Others

        14.4. Market Value Forecast, by Distribution Channel, 2017–2031

            14.4.1. Hospital Pharmacies

            14.4.2. Retail Pharmacies

            14.4.3. Online Pharmacies

        14.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            14.5.1. GCC Countries

            14.5.2. South Africa

            14.5.3. Rest of Middle East & Africa

        14.6. Market Attractiveness Analysis

            14.6.1. By Treatment Type

            14.6.2. By Source of Infection

            14.6.3. By Distribution Channel

            14.6.4. By Country/Sub-region

    15. Competition Landscape

        15.1. Market Player - Competition Matrix (by tier and size of companies)

        15.2. Market Share Analysis, by Company, 2021

        15.3. Company Profiles

            15.3.1. AstraZeneca

                15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.1.2. Product Portfolio

                15.3.1.3. SWOT Analysis

                15.3.1.4. Strategic Overview

            15.3.2. CorMedix, Inc.

                15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.2.2. Product Portfolio

                15.3.2.3. SWOT Analysis

                15.3.2.4. Strategic Overview

            15.3.3. Citus Pharmaceuticals

                15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.3.2. Product Portfolio

                15.3.3.3. SWOT Analysis

                15.3.3.4. Strategic Overview

            15.3.4. Fresenius Medical Care

                15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.4.2. Product Portfolio

                15.3.4.3. SWOT Analysis

                15.3.4.4. Strategic Overview

            15.3.5. Glenmark Pharmaceuticals Ltd.

                15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.5.2. Product Portfolio

                15.3.5.3. SWOT Analysis

                15.3.5.4. Strategic Overview

            15.3.6. Geistlich Pharma

                15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.6.2. Product Portfolio

                15.3.6.3. SWOT Analysis

                15.3.6.4. Strategic Overview

            15.3.7. Merck & Co., Inc.

                15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.7.2. Product Portfolio

                15.3.7.3. SWOT Analysis

                15.3.7.4. Strategic Overview

            15.3.8. Pfizer

                15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.8.2. Product Portfolio

                15.3.8.3. SWOT Analysis

                15.3.8.4. Strategic Overview

            15.3.9. TauroPhar GmbH

                15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.9.2. Product Portfolio

                15.3.9.3. SWOT Analysis

                15.3.9.4. Strategic Overview

            15.3.10. Xellia Pharmaceuticals Ltd.

                15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.10.2. Product Portfolio

                15.3.10.3. SWOT Analysis

                15.3.10.4. Strategic Overview

    List of Tables

    Table 01: Global Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031

    Table 02: Global Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, by Source of Infection, 2017–2031

    Table 03: Global Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 04: Global Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, by Region, 2017–2031

    Table 05: North America Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031

    Table 06: North America Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, by Source of Infection, 2017–2031

    Table 07: North America Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 08: North America Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, by Country, 2017–2031

    Table 09: Europe Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031

    Table 10: Europe Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, by Source of Infection, 2017–2031

    Table 11: Europe Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 12: Europe Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 13: Asia Pacific Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031

    Table 14: Asia Pacific Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, by Source of Infection, 2017–2031

    Table 15: Asia Pacific Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 16: Asia Pacific Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 17: Latin America Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031

    Table 18: Latin America Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, by Source of Infection, 2017–2031

    Table 19: Latin America Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 20: Latin America Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 21: Middle East & Africa Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031

    Table 22: Middle East & Africa Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, by Source of Infection, 2017–2031

    Table 23: Middle East & Africa Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 24: Middle East & Africa Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    List of Figures

    Figure 01: Global Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, 2017–2031

    Figure 02: Global Catheter-related Bloodstream Infections Market Analysis and Forecast, by Treatment Type, 2021 and 2031

    Figure 03: Global Catheter-related Bloodstream Infections Market Attractiveness Analysis, by Treatment Type, 2022–2031

    Figure 04: Global Catheter-related Bloodstream Infections Market Analysis and Forecast, by Source of Infection 2021 and 2031

    Figure 05: Global Catheter-related Bloodstream Infections Market Attractiveness Analysis, by Source of Infection, 2022–2031

    Figure 06: Global Catheter-related Bloodstream Infections Market Analysis and Forecast, by Distribution Channel, 2021 and 2031

    Figure 07: Global Catheter-related Bloodstream Infections Market Attractiveness Analysis, by Distribution Channel, 2022–2031

    Figure 08: Global Catheter-related Bloodstream Infections Market Analysis and Forecast, by Region, 2021 and 2031

    Figure 09: Global Catheter-related Bloodstream Infections Market Attractiveness Analysis, by Region, 2022–2031

    Figure 10: North America Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, 2017–2031

    Figure 11: North America Catheter-related Bloodstream Infections Market Analysis and Forecast, by Treatment Type, 2021 and 2031

    Figure 12: North America Catheter-related Bloodstream Infections Market Attractiveness Analysis, by Treatment Type, 2022–2031

    Figure 13: North America Catheter-related Bloodstream Infections Market Analysis and Forecast, by Source of Infection, 2021 and 2031

    Figure 14: North America Catheter-related Bloodstream Infections Market Attractiveness Analysis, by Source of Infection, 2022–2031

    Figure 15: North America Catheter-related Bloodstream Infections Market Analysis and Forecast, by Distribution Channel, 2021 and 2031

    Figure 16: North America Catheter-related Bloodstream Infections Market Attractiveness Analysis, by Distribution Channel, 2022–2031

    Figure 17: North America Catheter-related Bloodstream Infections Market Analysis and Forecast, by Country, 2021 and 2031

    Figure 18: North America Catheter-related Bloodstream Infections Market Attractiveness Analysis, by Country, 2022–2031

    Figure 19: Europe Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, 2017–2031

    Figure 20: Europe Catheter-related Bloodstream Infections Market Analysis and Forecast, by Treatment Type, 2021 and 2031

    Figure 21: Europe Catheter-related Bloodstream Infections Market Attractiveness Analysis, by Treatment Type, 2022–2031

    Figure 22: Europe Catheter-related Bloodstream Infections Market Analysis and Forecast, by Source of Infection, 2021 and 2031

    Figure 23: Europe Catheter-related Bloodstream Infections Market Attractiveness Analysis, by Source of Infection, 2022–2031

    Figure 24: Europe Catheter-related Bloodstream Infections Market Analysis and Forecast, by Distribution Channel, 2021 and 2031

    Figure 25: Europe Catheter-related Bloodstream Infections Market Attractiveness Analysis, by Distribution Channel, 2022–2031

    Figure 26: Europe Catheter-related Bloodstream Infections Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031

    Figure 27: Europe Catheter-related Bloodstream Infections Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 28: Asia Pacific Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, 2017–2031

    Figure 29: Asia Pacific Catheter-related Bloodstream Infections Market Analysis and Forecast, by Treatment Type, 2021 and 2031

    Figure 30: Asia Pacific Catheter-related Bloodstream Infections Market Attractiveness Analysis, by Treatment Type, 2022–2031

    Figure 31: Asia Pacific Catheter-related Bloodstream Infections Market Analysis and Forecast, by Source of Infection, 2021 and 2031

    Figure 32: Asia Pacific Catheter-related Bloodstream Infections Market Attractiveness Analysis, by Source of Infection, 2022–2031

    Figure 33: Asia Pacific Catheter-related Bloodstream Infections Market Analysis and Forecast, by Distribution Channel, 2021 and 2031

    Figure 34: Asia Pacific Catheter-related Bloodstream Infections Market Attractiveness Analysis, by Distribution Channel, 2022–2031

    Figure 35: Asia Pacific Catheter-related Bloodstream Infections Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031

    Figure 36: Asia Pacific Catheter-related Bloodstream Infections Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 37: Latin America Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, 2017–2031

    Figure 38: Latin America Catheter-related Bloodstream Infections Market Analysis and Forecast, by Treatment Type, 2021 and 2031

    Figure 39: Latin America Catheter-related Bloodstream Infections Market Attractiveness Analysis, by Treatment Type, 2022–2031

    Figure 40: Latin America Catheter-related Bloodstream Infections Market Analysis and Forecast, by Source of Infection, 2021 and 2031

    Figure 41: Latin America Catheter-related Bloodstream Infections Market Attractiveness Analysis, by Source of Infection, 2022–2031

    Figure 42: Latin America Catheter-related Bloodstream Infections Market Analysis and Forecast, by Distribution Channel, 2021 and 2031

    Figure 43: Latin America Catheter-related Bloodstream Infections Market Attractiveness Analysis, by Distribution Channel, 2022–2031

    Figure 44: Latin America Catheter-related Bloodstream Infections Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031

    Figure 45: Latin America Catheter-related Bloodstream Infections Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 46: Middle East & Africa Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, 2017–2031

    Figure 47: Middle East & Africa Catheter-related Bloodstream Infections Market Analysis and Forecast, by Treatment Type, 2021 and 2031

    Figure 48: Middle East & Africa Catheter-related Bloodstream Infections Market Attractiveness Analysis, by Treatment Type, 2022–2031

    Figure 49: Middle East & Africa Catheter-related Bloodstream Infections Market Analysis and Forecast, by Source of Infection, 2021 and 2031

    Figure 50: Middle East & Africa Catheter-related Bloodstream Infections Market Attractiveness Analysis, by Source of Infection, 2022–2031

    Figure 51: Middle East & Africa Catheter-related Bloodstream Infections Market Analysis and Forecast, by Distribution Channel, 2021 and 2031

    Figure 52: Middle East & Africa Catheter-related Bloodstream Infections Market Attractiveness Analysis, by Distribution Channel, 2022–2031

    Figure 53: Middle East & Africa Catheter-related Bloodstream Infections Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031

    Figure 54: Middle East & Africa Catheter-related Bloodstream Infections Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 55: Global Catheter-related Bloodstream Infections Market Share Analysis/Ranking, by Company, 2021

Copyright © Transparency Market Research, Inc. All Rights reserved